News Is BMS the next pharma takeover target? Speculation mounting that Pfizer and others could try for $90 bn plus merger
News Trump demands cuts to 'astronomical' drug prices - but pharm... Trump calls pharma leaders to White House to discuss cutting taxes, regulations - and drug prices
News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
News Mallinckrodt pays US authorities $100m in pricing case Price of epilepsy drug increased 85,000% since 2001, says FTC.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.